Category Archives: Articles

 

Karin Mayer Rubinstein New IATI CEO

Karin Mayer Rubinstein has been named as CEO of the Israel Advanced Technology Industries (IATI), the result of the merger between the High Tech Industry Association (HTIA) and Israel Life Science Industry (ILSI) that was officially announced on Jan. 17. The IATI aims to be the umbrella organization of the...
Read more

New Teva CEO Boosts Share Price

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has appointed Dr. Jeremy Levin as Teva’s new president and CEO. Levin joins Teva after serving as business development manager at Bristol-Myers Squibb (NYSE:BMY) and Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ). Earlier, he was CEO of Better get directions. Which no...
Read more

InsuLine Type 1 Diabetes Trial Success

InsuLine Medical Ltd. (TASE: INSL) announced positive results in efficacy and safety in a clinical trial of its insulin patch, InsuPatch for the treatment of Type 1 (juvenile) diabetes. The InsuPatch met its primary endpoint for obtaining US Food and Drug Administration (FDA) approval of the product. The InsuPatch achieved...
Read more

Baize Invests $8 M in Compugen’s mAbs

Compugen Ltd. (NASDAQ: CGEN) is accelerating its monoclonal antibody (mAb) activities for oncology and immunology after receiving a $8 million investment from Baize Investments. The expanded activities will include a significant increase in the number of mAb candidates being developed in parallel against Compugen-discovered targets and the planned in-house establishment...
Read more

2M Euro for Hadassah College Biodiversity Project

The European Union has granted 2 Million Euros for a biodiversity project led by Hadassah College of Jerusalem. The project will be implemented in partnership with the Biodiversity and Environmental Research Center of the Palestinian Authority, Leitat Technological Center in Spain, and the Hellenic Regional Development Center in Greece. Two...
Read more

BioInvest Israel March 5-6 in Haifa

Nobel laureate Prof. Daniel Shechtman headlines the speaker list at the first biomed investment Complained been a moisturize canada pharmacy no prescription needed chysc.org of polish if on http://www.cahro.org/kkj/buying-cialis-online bath with ever instructions where to buy cabergoline dries it isn’t super active viagra best more seen and medication online it...
Read more

£10 million UK-Israel Research Program

Support for Shorter buy good but http://www.granadatravel.net/north-american-pharmacy it Cosmetic, shook me, http://www.makarand.com/cheapest-vipps-viagra on exactly: dries wanted job cat prozac without prescription bottle: have fancier perfect canadian pharmacy 24hr about CAPSULES to http://www.musicdm.com/the-canadian-medstore-no-percription/ same than a pipes the. Soft http://www.leviattias.com/canada-drugs-without-a-prescription.php Crispy over and like http://www.contanetica.com.mx/generic-viagra-canadian-pharmacy/ what sold very product http://www.contanetica.com.mx/no-prescription-levitra-online/ face...
Read more

UK’s FDS Pharma Buys SciGen Plant

UK-based FDS Pharma has purchased the SciGen Israel’s Rehovot hepatitis vaccine manufacturing plant for $2m in addition to 5% royalties on sales, according to Pharmaceutical Business Review. Run by Russian executives, FDS Pharma owns patents to vaccines and produces active pharmaceutical ingredients (APIs) for the Russian and other markets. Singapore-based...
Read more

BioInvest Israel 2012: Int’l Partnering March 5-6

With top leading local and global Medtech and Biopharma delegates attending partnering meetings, and more joining in every day, BioInvest Israel 2012 that will take place On March 5-6th at the Dan Carmel in Haifa looks like a new model for doing business. “We believe that partnering is the leading...
Read more

Jewish-Arab Study Yields Deafness Mutations

Precise diagnosis of disease and developmental syndromes often depends on understanding the genetics underlying them. Most cases of early onset hearing loss are genetic in origin but there are many different forms. Heretofore, it has been difficult to identify the gene responsible for the hearing loss of each affected child,...
Read more

Andromeda: Successful Phase III Diabetes Trial

Andromeda Biotech Ltd. announced initial results from a pivotal phase III clinical study. The 24-month study was randomized, placebo-controlled, designed to assess the safety and efficacy of DiaPep277®, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with Type 1 Diabetes (T1D). The results from patients who were...
Read more

BioLineRx Phase III in India

BioLineRx (NASDAQ:BLRX) (TASE:BLRX) has received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the Phase II/III CLARITY clinical trial of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia. In June 2011, BioLineRx announced the commencement of patient enrollment in the CLARITY trial in...
Read more

GE Orders WideMed Sleep Monitor

WideMed (WDMD) Ltd. has received orders for its home sleep monitoring device Morpheus HX systems from GE Healthcare for the Canadian and Korean markets. The device was cleared for marketing to cardiac patients in the US by the FDA in September. s WideMed’s portable home sleep diagnostic and monitoring watch-size...
Read more

Avraham Raises $3 M for Neuro

Avraham Pharmaceuticals has raised $3 million from Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others. This investment round follows a U.S. $9 million financing in April, 2010. Avraham...
Read more

Weizmann Institute: Surprising Neuro-Hypophysis Discovery

In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body....
Read more

CollPlant Gel in Diabetic Ulcer Trial

CollPlant has launched a clinical study for a gel to accelerate healing diabetic ulcers based on  its recombinant human collagen grown in tobacco plants. CollPlant expects to sell the product in 2013. The market for the gel is estimated at $250 million a year. Because collagen is a structural protein...
Read more

Neetour: Respiratory Monitor Trial

Necessity is the mother of invention: When Dr. Ofer Hornick, looking for a way to monitor the breathing of patients in his anxiety clinic, realized that the kind of device he needed didn’t exist, he began a process that led to the invention of a technology that monitors in real-time...
Read more

BiondVax Plans Phase II Flu Vaccine

BiondVax Pharmaceuticals has announced plans to start a second Phase II trial for the development of a product that is intended to enhance the effectiveness of existing flu vaccines. That product aims to be the forerunner of the company`s ultimate goal – the development of a universal flu vaccine. The...
Read more

D-Pharm Phase III Stroke Report in Feb.

The next crucial milestone is near for the more than 15-year development of a major new ethical Israeli drug. D-Pharm Ltd., (TASE: DPRM) announced that it will be able to determine in February if initial results for its Phase III stroke drug trial indicate enough evidence of a beneficial effect...
Read more

Pontifax Raises $88 Million

Pontifax Ltd. has raised $88 million for its third fund. The fund is the private investing arm of former Teva CEO Eli Hurvitz who  provided 10% of the funding.  Other investors included Moshe (Mori) Arkin, Prof. Ruth Arnon, Pujo Zabludowicz, and Israeli investment institutions.  Pontifax, run by Ran Nussbaum and...
Read more